Trump Team Outlines Healthcare Agenda—No Mention of Drug Prices
Xconomy
NOVEMBER 10, 2016
There is no mention of drug pricing or what the administration might do about frequent price increases, such as Mylan’s EpiPen practice, that critics say are unsubstantiated and unethical. Health savings accounts will be part of the mix, the site says. It doesn’t necessarily allude to drug-price negotiation.
106 
Let's personalize your content